Cue Biopharma (NASDAQ:CUE) Issues Earnings Results

Cue Biopharma (NASDAQ:CUE) released its earnings results on Thursday. The company reported ($1.08) EPS for the quarter, FiscalAI reports. The firm had revenue of $5.69 million during the quarter. Cue Biopharma had a negative net margin of 96.85% and a negative return on equity of 165.19%.

Cue Biopharma Price Performance

NASDAQ CUE traded down $4.14 during trading on Thursday, hitting $25.33. 160,873 shares of the company’s stock traded hands, compared to its average volume of 1,454,664. The stock has a fifty day moving average of $231.49 and a two-hundred day moving average of $336.55. Cue Biopharma has a 12-month low of $4.97 and a 12-month high of $41.42. The firm has a market cap of $99.80 million, a P/E ratio of -2.64 and a beta of 2.37.

Institutional Trading of Cue Biopharma

Several institutional investors have recently added to or reduced their stakes in CUE. GC Wealth Management RIA LLC boosted its position in Cue Biopharma by 35.0% during the fourth quarter. GC Wealth Management RIA LLC now owns 4,631,644 shares of the company’s stock valued at $1,415,000 after buying an additional 1,200,000 shares during the period. Boothbay Fund Management LLC purchased a new stake in Cue Biopharma during the third quarter valued at about $439,000. Texas Capital Bank Wealth Management Services Inc boosted its holdings in shares of Cue Biopharma by 1,231.2% during the fourth quarter. Texas Capital Bank Wealth Management Services Inc now owns 440,670 shares of the company’s stock worth $135,000 after purchasing an additional 407,568 shares during the period. Squarepoint Ops LLC purchased a new stake in shares of Cue Biopharma during the third quarter worth about $62,000. Finally, Northwestern Mutual Wealth Management Co. boosted its holdings in shares of Cue Biopharma by 730.0% during the second quarter. Northwestern Mutual Wealth Management Co. now owns 83,000 shares of the company’s stock worth $57,000 after purchasing an additional 73,000 shares during the period. 35.04% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

CUE has been the topic of a number of research analyst reports. Weiss Ratings reissued a “sell (e+)” rating on shares of Cue Biopharma in a research note on Friday, March 27th. Wall Street Zen upgraded shares of Cue Biopharma from a “buy” rating to a “strong-buy” rating in a research report on Monday. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat, Cue Biopharma currently has a consensus rating of “Sell”.

Cue Biopharma Company Profile

Cue Biopharma is a clinical‐stage biotechnology company focused on the development of next‐generation immunotherapies for cancer and infectious diseases. The company’s proprietary platform, known as Cytokine Release & Targeting (CRT), is designed to deliver cytokine payloads directly to antigen‐specific T cells in order to enhance immune responses within targeted tissues. This approach aims to improve the therapeutic index of cytokine treatments by limiting systemic exposure and potentiating localized immune activation.

Founded in 2015 and headquartered in Cambridge, Massachusetts, Cue Biopharma has advanced multiple lead programs into early‐stage clinical studies.